Pros | 5Y returns in the top 25% of the category. Beats FD returns for both 3Y & 5Y duration. | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | 5Y returns in the bottom 25% of the category. 3Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 9 Years | 12 Years | ||
Fund Size | 1325 Cr | 8346 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.62% | 0.89% | ||
Exit Load | 0.25% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (9.59%) Apollo Hospitals Enterprise Ltd (5.06%) HealthCare Global Enterprises Ltd (4.96%) Lupin Ltd (4.9%) Max Healthcare Institute Ltd Ordinary Shares (4.71%) | Sun Pharmaceuticals Industries Ltd (12.67%) Divi's Laboratories Ltd (8.07%) Lupin Ltd (7.26%) Cipla Ltd (6.29%) Apollo Hospitals Enterprise Ltd (5.97%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (97.8%) Basic Materials (2.2%) | Health (100%) | ||
Equity % | 98.5% | 99.66% | ||
Debt % | - | - | ||
P/E | - | - | ||
P/B | - | - | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.05% | -0.35% | ||
3-Month Return | 0.07% | 0.57% | ||
6-Month Return | 4.56% | 1.77% | ||
1-Year Return | 1.19% | 0.37% | ||
3-Year Return | 23.32% | 22.07% | ||
5-Year Return | 17.92% | 17.19% |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Rajat Srivastava | Sailesh Raj Bhan,Lokesh Maru,Divya Sharma,Kinjal Desai |